Despite a consistent and significant reduction in tumor burden in a KrasG12D-driven genetically engineered tumor model and in patient-derived xenografts, SGLT2 inhibition was not able to completely block tumor development [14], and the tumors that developed during chronic canagliflozin treatment were less differentiated than tumors in the placebo group [86]. Here, SLC5A2 is linked to neoplasm.